Elamipretide

Elamipretide is a mitochondria-targeting tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane to stabilize cristae structure, reduce oxidative stress, enhance ATP production, and treat Barth syndrome.

Brief glance

The primary outcome is Longevity, but it's also used for Anti-Aging, Metabolic, Recovery & Repair. This compound is considered a Peptide. It is also known as SS-31, MTP-131, Bendavia. It may be compounded in 503A pharmacies where allowed. It is not listed under a DEA schedule.

Overview

Elamipretide is a synthetic tetrapeptide and mitochondrial cardiolipin binder that selectively targets the inner mitochondrial membrane to stabilize cristae structure, reduce reactive oxygen species, and enhance ATP production. It is approved for improving muscle strength in patients with Barth syndrome and has been investigated for other mitochondrial dysfunction-related conditions such as primary mitochondrial myopathy and Leber's hereditary optic neuropathy. Administered subcutaneously as the hydrochloride salt, it addresses key aspects of mitochondrial bioenergetics in these rare diseases.

Elamipretide is a synthetic mitochondria-targeting tetrapeptide that selectively binds to cardiolipin in the inner mitochondrial membrane. This interaction stabilizes mitochondrial cristae structure, reduces reactive oxygen species production and oxidative stress, and enhances adenosine triphosphate production to address mitochondrial dysfunction. As a pharmaceutical active ingredient, it is approved under the brand name FORZINITY for improving muscle strength in patients with Barth syndrome, a rare genetic disorder involving mitochondrial impairment. Its therapeutic potential extends to investigational uses in other conditions linked to mitochondrial deficits, such as cardiovascular diseases and Leber's hereditary optic neuropathy.

Benefits

Elamipretide is a mitochondrial-targeted peptide therapeutic that improves cellular energy production by binding to cardiolipin in the inner mitochondrial membrane, thereby enhancing ATP synthesis and reducing reactive oxygen species formation¹,². The drug's primary clinical indication is Barth syndrome, a rare genetic disorder characterized by mitochondrial dysfunction; the FDA accepted its new drug application for this indication in April 2024, designating it as the only late-stage therapeutic candidate for this condition¹. Beyond Barth syndrome, elamipretide has demonstrated therapeutic potential in various mitochondrial disorders including primary mitochondrial myopathy, Friedreich's ataxia, chronic progressive external ophthalmoplegia, and neuropathy, ataxia, and retinitis pigmentosa syndrome, with clinical case evidence showing significant improvements in muscle strength, stamina, balance, and overall quality of life within weeks of treatment initiation³,⁴. Preclinical and early clinical data also suggest possible benefits in age-related conditions such as heart failure, ischemia-reperfusion injury, and dry age-related macular degeneration, though these remain under investigation⁴. Elamipretide is administered as subcutaneous injections at doses of 40–60 mg daily and has demonstrated good tolerability across patient populations, including pediatric patients with rare orphan mitochondrial diseases³.

Side effects

Common side effects of elamipretide include injection site reactions such as redness, itching, pain, bruising, swelling, induration, urticaria, or nodules, as well as headache, dizziness, abdominal pain, flatulence, nausea, diarrhea, and increased eosinophil count, most of which are mild to moderate and tend to improve over time.²,⁵,⁶,⁷,⁸,⁹,¹⁰ Serious side effects may include severe allergic reactions or anaphylaxis, manifesting as rash, hives, cough, shortness of breath, chest tightness, difficulty swallowing, fast heartbeat, swelling of the face/lips/tongue, or unusual tiredness, requiring immediate medical attention.⁵,⁷,⁸ The drug contains benzyl alcohol, which can cause serious reactions like gasping syndrome in newborns or premature infants.⁷ Elamipretide is generally well-tolerated in clinical trials with low rates of serious adverse events not deemed treatment-related, but regular monitoring including blood tests is recommended to check for unwanted effects.⁷,¹⁰,¹¹ No specific contraindications are established, and safety data in pregnancy or breastfeeding are lacking.²,⁶ Report any unusual or persistent side effects to a healthcare provider or the FDA.²,⁵,⁶

Mechanisms of action

Elamipretide, a synthetic tetrapeptide, localizes to the inner mitochondrial membrane through electrostatic interactions between its positively charged residues (D-Arg and Lys) and the negatively charged cardiolipin phospholipid.¹²,¹³ This binding stabilizes cardiolipin, preserves mitochondrial cristae structure, prevents cardiolipin peroxidation, and maintains membrane potential.¹²,¹³ By associating with cardiolipin, it enhances the assembly and activity of electron transport chain complexes (I, III, IV) and supercomplexes, improving electron transfer efficiency, ATP production, and reducing reactive oxygen species generation.¹²,¹³,¹⁴ These actions inhibit mitochondrial permeability transition pore opening, mitigating oxidative stress and cellular damage in conditions like heart failure.¹²,¹⁴